NI202000095A - Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión - Google Patents

Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión

Info

Publication number
NI202000095A
NI202000095A NI202000095A NI202000095A NI202000095A NI 202000095 A NI202000095 A NI 202000095A NI 202000095 A NI202000095 A NI 202000095A NI 202000095 A NI202000095 A NI 202000095A NI 202000095 A NI202000095 A NI 202000095A
Authority
NI
Nicaragua
Prior art keywords
bupropion
methods
plasma levels
tetrabenazine
dihydrotetrabenazine
Prior art date
Application number
NI202000095A
Other languages
English (en)
Inventor
Tabuteau Herriot
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of NI202000095A publication Critical patent/NI202000095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta divulgación se refiere a métodos que administran bupropión, como S-bupropión o R-bupropión, junto con tetrabenazina, alfa-dihidrotetrabenazina o beta-dihidrotetrabenazina a un ser humano. También se describen formas de dosificación, sistemas de administración de fármacos y métodos relacionados con tetrabenazina, alfa-dihidrotetrabenazina o beta-dihidrotetrabenazina y bupropión, como S-bupropión o R-bupropión.
NI202000095A 2018-06-10 2020-12-09 Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión NI202000095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682998P 2018-06-10 2018-06-10
US201862683399P 2018-06-11 2018-06-11

Publications (1)

Publication Number Publication Date
NI202000095A true NI202000095A (es) 2021-06-22

Family

ID=68843534

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000095A NI202000095A (es) 2018-06-10 2020-12-09 Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión

Country Status (17)

Country Link
EP (1) EP3790538A4 (es)
JP (2) JP2021529826A (es)
KR (2) KR20240034871A (es)
CN (1) CN112292121A (es)
AU (2) AU2019284477B2 (es)
BR (1) BR112020025064A2 (es)
CA (1) CA3101375A1 (es)
CL (1) CL2020003189A1 (es)
CO (1) CO2021000037A2 (es)
CR (1) CR20200616A (es)
EC (1) ECSP20082568A (es)
IL (1) IL279332A (es)
MX (1) MX2020013385A (es)
NI (1) NI202000095A (es)
PE (1) PE20210370A1 (es)
SG (1) SG11202011762VA (es)
WO (1) WO2019241162A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
US10105327B2 (en) * 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US9707191B2 (en) * 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
PL3265085T3 (pl) * 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
MX2017017015A (es) * 2015-06-23 2018-02-26 Neurocrine Biosciences Inc Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.

Also Published As

Publication number Publication date
CO2021000037A2 (es) 2021-01-18
PE20210370A1 (es) 2021-02-26
JP2024059744A (ja) 2024-05-01
KR20210018914A (ko) 2021-02-18
MX2020013385A (es) 2021-05-27
EP3790538A4 (en) 2021-06-30
CA3101375A1 (en) 2019-12-19
AU2019284477B2 (en) 2022-08-11
IL279332A (en) 2021-01-31
CN112292121A (zh) 2021-01-29
JP2021529826A (ja) 2021-11-04
BR112020025064A2 (pt) 2021-03-23
SG11202011762VA (en) 2020-12-30
WO2019241162A1 (en) 2019-12-19
EP3790538A1 (en) 2021-03-17
CL2020003189A1 (es) 2021-05-28
KR20240034871A (ko) 2024-03-14
ECSP20082568A (es) 2021-02-26
CR20200616A (es) 2021-03-15
AU2022268331A1 (en) 2022-12-15
AU2019284477A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
UY37686A (es) Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables
CO2017001994A2 (es) Compuestos activos hacia bromodominios
ECSDI18019182S (es) Dispositivo intranasal para suministro de fármacos
CL2020003174S1 (es) Dispositivo para administración de dosis.
ECSP19084085A (es) Inhibidores pirazólicos de magl
CO2019005059A2 (es) Inhibidores de magl
CO2019005038A2 (es) Inhibidores de magl
DOP2017000087A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
CO2019005552A2 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
DOP2019000295A (es) Inhibidores pirazólicos de magl
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
NI202000095A (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
CL2022001486A1 (es) Formulaciones de anticuerpos anti-pd-l1.
ECSP21079422A (es) Método para preparar formulaciones de péptidos estables
UA135395U (uk) Комбінований лікарський засіб снодійной дії
ECSP17025904A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos